Eben Tessari Sells 14,000 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00. Following the completion of the sale, the chief operating officer now directly owns 81,975 shares in the company, valued at $1,604,250.75. This represents a 14.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Eben Tessari also recently made the following trade(s):

• On Monday, January 13th, Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total transaction of $255,360.00.

Kiniksa Pharmaceuticals Price Performance

Shares of NASDAQ:KNSA opened at $19.28 on Thursday. The firm has a fifty day moving average of $19.88 and a two-hundred day moving average of $22.96. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $16.56 and a 12-month high of $28.15.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several institutional investors have recently bought and sold shares of KNSA. Wellington Management Group LLP acquired a new stake in Kiniksa Pharmaceuticals in the 3rd quarter worth $1,192,000. JPMorgan Chase & Co. bought a new position in Kiniksa Pharmaceuticals in the 3rd quarter valued at $4,997,000. Parkman Healthcare Partners LLC lifted its position in Kiniksa Pharmaceuticals by 16.7% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock worth $18,874,000 after buying an additional 108,102 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the third quarter worth approximately $675,000. Finally, SG Americas Securities LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at $355,000. 53.95% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

KNSA has been the topic of a number of recent research reports. Evercore ISI raised their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Wedbush reiterated an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Monday, January 13th. Finally, JPMorgan Chase & Co. upped their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $36.60.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.